Clinical Trials Logo

Clinical Trial Summary

The aim of the study is to evaluate if it is possible to mark with a wire colorectal hepatic metastases after complete response to a neoadjuvant chemotherapy.Primary the investigators want to investigate if the wire marking is a possibility to mark respectively to identify these lesions. Further the investigators want to evaluate how many patients with complete radiologic have complete histologic response in their specimen respectively in how many specimens in the definitive histology tumor cells are visible.


Clinical Trial Description

Colorectal Cancer is most common in western countries. In 2007 in Austria 4462 new colorectal cancers were diagnosed. The most common place of metastasis is the liver. Approximately 15% of patients have metastasis at time of diagnosis of primary tumor and further 50% will develop metastases in the further course of the disease.However only 10-25% of patients are candidates for liver resection. New chemotherapeutics, new targeted therapies with monoclonal antibodies and better surgical techniques improved response rates, resection rates and overall survival. Owing to improved response rates metastases in the liver partially respectively completely disappeared, so that these lesions are not more visible in apparative diagnostic like CT-scan and MRI.

The question is now what to do with this patients? In the literature there is no evidence how to manage these patients. Conservative management would lead to a reoccurrence of metastases in the liver. On the other side surgical management is difficult, because metastases are preoperatively and intraoperatively not visible and resection is only possible with the removement of greater amounts of healthy tissue.

The computer tomography-guided wire marking of the metastases in the liver is a possibility to overcome these problems. All patients with complete radiologic response of metastases in the liver and metastases ≤ 1 cm are included in the study (RECISTE-Criteria). On day of surgical procedure patients will brought to interventional radiologist and based on computer tomography images before neoadjuvant chemotherapy the lesions will be marked computer tomography-guided with a wire(X-Reidy Breast Lesion Localization Needle, Cook Medical). The wire is placed percutaneously and under antibiotic prophylaxis. After the marking procedure, the patient is brought into the operating room to resect the metastases in the liver. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01457599
Study type Observational
Source Medical University of Graz
Contact
Status Completed
Phase N/A
Start date July 2011
Completion date August 2016

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02758977 - Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM) N/A
Terminated NCT02820194 - A Trial on SBRT Versus MWA for Inoperable Colorectal Liver Metastases (CLM) N/A
Completed NCT02843802 - Combination of Cryosurgery and NK Immunotherapy for Advanced Liver Cancer Phase 1/Phase 2
Not yet recruiting NCT02647047 - Spinal Versus Epidural Analgesia in Laparotomic Liver Surgery N/A
Active, not recruiting NCT01516710 - Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study N/A
Completed NCT02391207 - Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence N/A
Recruiting NCT03889093 - Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System N/A
Completed NCT01423734 - The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Recruiting NCT02886104 - Comparison of Hepatectomy and Local Ablation for Resectable Synchronous and Metachronous Colorectal Liver Metastasis N/A
Completed NCT00199173 - Comparing Hepatic Intra-arterial Injection of Yttrium-90 Microspheres Versus Fluorouracil (5FU) in Colorectal Cancer Metastatic to the Liver Only Phase 3